Clarity

Aclarion Appoints Greg Gould as Chief Financial Officer

Sep 3, 2025

HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening financial integrity Broomfield, CO, September 3, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is...

Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts

Aug 5, 2025

Nociscan YOY scan volume increased 132% from Q2 2024 to Q2 2025 fueled by new physician adoption and insurance company coverage in the UK Company has achieved two consecutive quarters of scan volume growth for the first time and expects continued QOQ growth for the remainder of the year Cost-effectiveness analysis demonstrating Nociscan is more effective and less costly than provocative discography published in peer-reviewed journal adding critical evidence in support of payer coverage Pivotal...

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Jun 25, 2025

The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Company reaffirms internal interim results of CLARITY...

Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site

Jun 10, 2025

UHealth — University of Miami Health System and the University of Miami Miller School of Medicine provide world-class research and renowned clinical expertise in spine surgery CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., June 10,...

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

May 12, 2025

Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”)...

Aclarion Welcomes Advocate Health as CLARITY Trial Site

May 5, 2025

Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Press Audio: BROOMFIELD, Colo., May 05, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

Aclarion Announces Reverse Stock Split

Mar 26, 2025

BROOMFIELD, Colo., March 26, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (NASDAQ: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Friday March 28, 2025, it will complete a 1-for-27 reverse stock split of its common stock. On September 23, 2024, the Company’s stockholders...

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Feb 11, 2025

Recent Notice of Allowance is for Aclarion’s 24th issued US patent Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an intervertebral disc Patent will expand Aclarion’s proprietary rights to use MRS to measure propionic acid as a biomarker for the identification of potential infection and pain throughout the body Broomfield, CO, February 11, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Feb 6, 2025

Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed to demonstrate Nociscan’s ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 6, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),...

NEWSROOM

Aclarion Appoints Greg Gould as Chief Financial Officer

Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

Aclarion Welcomes Advocate Health as CLARITY Trial Site

Aclarion Announces Reverse Stock Split

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Contact Us